- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Evolution of Personalized Medicine and Positive Outcomes
Personalized medicine has changed considerably following rapid developments in the technology, both in terms of things that can be addressed by genetic and genomic information, as well as sophisticated methods that have been devised to be able to use this information, according to Edmund Pezalla, MD, MPH.
Particularly in oncology, Pezalla thinks drug development has been the primary driver for the use of personalized medicine—drugs that are targeted for specific markers expressed on particular tumor types. “That has been extremely helpful in getting patients the right therapies. The sophistication has vastly improved and that has definitely helped.”
The early phase of personalized medicine, he explained, was used to test drug metabolism and other things that did not yield improved patient outcomes or lead to better treatment decisions. Pezalla believes this scenario has now changed, both in oncology and other therapeutic areas such as, rheumatoid arthritis.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
